Day: April 15, 2026

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) — The global insurance industry is entering a new phase in which investments in technology, data and automation must translate into tangible improvements in underwriting performance, capital efficiency and customer outcomes, according to the 2026 Outlook for insurers from Alpha FMC, a leading global consultancy to the financial services industry. The report, which is based on qualitative research conducted by global leadership teams in the insurance industry, highlights how insurers are now starting to move beyond technology modernisation and experimentation with artificial intelligence (AI), to embed these technologies across underwriting, claims and operational workflows to deliver measurable commercial advantage. According to the report, the insurance sector has remained resilient in...

Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platformWASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced ARAKODA® (tafenoquine) for malaria prevention is now available for purchase on the Runway Health website, for U.S. travelers seeking more convenient protection against malaria before visiting endemic regions. Patients can now conveniently connect with a licensed healthcare professional on Runway Health, who will independently determine whether a prescription for ARAKODA is appropriate, and then have the malaria preventive delivered to their address pre-departure. ARAKODA...

ATHENS, Greece, April 15, 2026 (GLOBE NEWSWIRE) — Capital Clean Energy Carriers Corp. (NASDAQ: CCEC) (“CCEC” or the “Company”) today announced that it has agreed to sell the LNG/C Amore Mio I (2023-built 174,000 cbm) to a subsidiary of a joint venture company (the “Joint Venture”) owned 51% by CCEC and 49% by a company affiliated with global energy trader BGN Group in the first quarter of 2027. The Joint Venture has secured a 10-year time charter (with two three-year extension options) of the vessel to BGN INT DMCC commencing simultaneously with the acquisition of the vessel and expected to generate aggregate revenues (including all options) of up to approximately $485.6 million and extending up to 2043 if all options are exercised. Joint Venture Structure The Joint Venture will be effected through BM Capital HoldCo LLC, a newly...

MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (Frankfurt: ABB.F) (“Volatus” or the “Company”), a Canadian-controlled global aerospace and defence company delivering integrated uncrewed systems, aerial intelligence, and mission-critical operational services, today announced it has been awarded a multi-year contract to provide specialist training to a NATO-allied government ministry. The contract has an initial term of two years, with renewal options that could extend the total engagement to approximately CAD $2.1 million in aggregate value, subject to the exercise of such options. The award was secured through a competitive procurement process under an established government framework. Under the agreement, Volatus will design, develop, and deliver a portfolio of advanced training programs...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. QUEBEC CITY, April 15, 2026 (GLOBE NEWSWIRE) — Kobo Resources Inc. (“Kobo” or the “Company”) (TSX.V: KRI) is pleased to announce that it has closed its previously announced non-brokered private placement of common shares of the Company (“Common Shares”) for gross proceeds of $5,528,882.89 (the “Offering”). Under the Offering, 16,504,128 Common Shares were issued at a price of $0.335 per Common Share. Funde Investment Open-ended Fund Company – Funde Investment Chang Ying No.1 Fund (“Funde”) participated in the Offering as a lead investor for an amount of $4.53 million. Following the completion of the Offering, Funde beneficially owns 13,519,053...

Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide adoption and long-term commercialization strategy for REYOBIQ™ HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence...

MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 21, 2026, at 2:00 p.m. ET at the Metro Toronto Convention Centre (North Building) in Toronto. A copy of the presentation will be available at www.knighttx.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and...

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B (“cHBV”). “We are excited about the potential of imdusiran, which in trials has achieved functional cure for 10 chronic hepatitis B patients to date and allowed many others to live medication-free, to address significant unmet medical need,” said Lindsay Androski, President and CEO of Arbutus. “The FDA grant of Fast Track designation validates imdusiran as an important drug...